JP2016500088A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016500088A5 JP2016500088A5 JP2015543424A JP2015543424A JP2016500088A5 JP 2016500088 A5 JP2016500088 A5 JP 2016500088A5 JP 2015543424 A JP2015543424 A JP 2015543424A JP 2015543424 A JP2015543424 A JP 2015543424A JP 2016500088 A5 JP2016500088 A5 JP 2016500088A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- active ingredient
- tolterodine
- controlled release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 65
- 239000004480 active ingredient Substances 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 22
- 239000011324 bead Substances 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 14
- 229960004045 tolterodine Drugs 0.000 claims description 12
- 229940079593 drugs Drugs 0.000 claims description 11
- 239000011159 matrix material Substances 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 230000001022 anti-muscarinic Effects 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 8
- 206010020853 Hypertonic bladder Diseases 0.000 claims description 7
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims description 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 206010029446 Nocturia Diseases 0.000 claims description 5
- TWHNMSJGYKMTRB-CDHDNNKHSA-N (2R,3R)-2,3-dihydroxybutanedioic acid;2-[(1S)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1([C@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 TWHNMSJGYKMTRB-CDHDNNKHSA-N 0.000 claims description 4
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 claims description 4
- 239000001856 Ethyl cellulose Substances 0.000 claims description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 4
- 239000002160 alpha blocker Substances 0.000 claims description 4
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 4
- 229920001249 ethyl cellulose Polymers 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 238000000859 sublimation Methods 0.000 claims description 4
- 229960003553 tolterodine tartrate Drugs 0.000 claims description 4
- 239000000651 prodrug Chemical group 0.000 claims description 3
- 229940002612 prodrugs Drugs 0.000 claims description 3
- PUSNGFYSTWMJSK-GSZQVNRLSA-N (2R,3R,4S,5R,6R)-2,3,4-trimethoxy-6-(methoxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxyoxane;1-[[(2R,3R,4S,5R,6S)-3,4,5-tris(2-hydroxypropoxy)-6-[(2R,3R,4S,5R,6R)-4,5,6-tris(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)oxan- Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](OC)O[C@@H]1COC.CC(O)CO[C@@H]1[C@@H](OCC(C)O)[C@H](OCC(C)O)[C@@H](COCC(O)C)O[C@H]1O[C@H]1[C@H](OCC(C)O)[C@@H](OCC(C)O)[C@H](OCC(C)O)O[C@@H]1COCC(C)O PUSNGFYSTWMJSK-GSZQVNRLSA-N 0.000 claims description 2
- 241000220479 Acacia Species 0.000 claims description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 2
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims description 2
- 229960002845 Desmopressin Acetate Drugs 0.000 claims description 2
- 229920001202 Inulin Polymers 0.000 claims description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N Inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
- 229940029339 Inulin Drugs 0.000 claims description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 2
- AIHDCSAXVMAMJH-GFBKWZILSA-N Levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- 239000005913 Maltodextrin Substances 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 239000004373 Pullulan Substances 0.000 claims description 2
- 229920001218 Pullulan Polymers 0.000 claims description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N Raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 2
- 229940005550 Sodium alginate Drugs 0.000 claims description 2
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 230000001419 dependent Effects 0.000 claims description 2
- YNKFCNRZZPFMEX-XHPDKPNGSA-N desmopressin acetate trihydrate Chemical group O.O.O.CC(O)=O.C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 YNKFCNRZZPFMEX-XHPDKPNGSA-N 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 229940035034 maltodextrin Drugs 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 230000035699 permeability Effects 0.000 claims description 2
- 235000019423 pullulan Nutrition 0.000 claims description 2
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 229960002613 tamsulosin Drugs 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 229920003176 water-insoluble polymer Polymers 0.000 claims description 2
- 229920003169 water-soluble polymer Polymers 0.000 claims description 2
- 210000002700 Urine Anatomy 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN3575DE2012 | 2012-11-21 | ||
IN3575/DEL/2012 | 2012-11-21 | ||
IN3947/DEL/2012 | 2012-12-20 | ||
IN3947DE2012 | 2012-12-20 | ||
PCT/EP2013/074373 WO2014079922A1 (en) | 2012-11-21 | 2013-11-21 | Composition for immediate and extended release |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016500088A JP2016500088A (ja) | 2016-01-07 |
JP2016500088A5 true JP2016500088A5 (ru) | 2016-11-17 |
Family
ID=49619947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015543424A Pending JP2016500088A (ja) | 2012-11-21 | 2013-11-21 | 即時放出および持続放出のための組成物 |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP2922525A1 (ru) |
JP (1) | JP2016500088A (ru) |
KR (1) | KR20150085826A (ru) |
CN (1) | CN104797240A (ru) |
AR (1) | AR093585A1 (ru) |
AU (1) | AU2013349682A1 (ru) |
BR (1) | BR112015011430A2 (ru) |
CA (1) | CA2891365A1 (ru) |
EA (1) | EA201590805A1 (ru) |
HK (1) | HK1213779A1 (ru) |
IL (1) | IL238648A0 (ru) |
IN (1) | IN2015DN03984A (ru) |
MX (1) | MX2015006399A (ru) |
PH (1) | PH12015501096A1 (ru) |
SG (2) | SG11201503913TA (ru) |
TW (1) | TW201422254A (ru) |
WO (1) | WO2014079922A1 (ru) |
ZA (1) | ZA201503603B (ru) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20240015735A (ko) | 2013-07-23 | 2024-02-05 | 세레니티 파마슈티컬즈 엘엘씨 | 베타-3-아드레날린 수용체 작용제와 함께 데스모프레신을 포함하는 방법 및 조성물 |
KR20150144209A (ko) * | 2014-06-16 | 2015-12-24 | 훼링 비.브이. | 안정화된 데스모프레신 또는 이의 약학적으로 허용가능한 염을 함유 약학 조성물 |
KR20240010751A (ko) * | 2014-11-20 | 2024-01-24 | 세레니티 파마슈티컬즈 엘엘씨 | 알파-아드레날린성 수용체 길항제와 조합된 데스모프레신을 포함하는 방법 및 조성물 |
US9931344B2 (en) | 2015-01-12 | 2018-04-03 | Nano Pharmaceutical Laboratories, Llc | Layered sustained-release microbeads and methods of making the same |
EP3288556A4 (en) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
SG11201805810PA (en) * | 2015-09-01 | 2018-08-30 | Wellesley Pharmaceuticals Llc | Extended, delayed and immediate release formulation method of manufacturing and use thereof |
KR20180066113A (ko) * | 2015-09-30 | 2018-06-18 | 웰즐리 파마슈티컬스 엘엘씨 | 배뇨 빈도 감소용 조성물, 제조 방법 및 용도 |
SG11201805530RA (en) * | 2015-09-30 | 2018-07-30 | Wellesley Pharmaceuticals Llc | Composition for reducing the frequency of urination, method of making and use thereof |
TW201726114A (zh) * | 2015-11-23 | 2017-08-01 | 魏斯理製藥公司 | 降低排尿頻率之組成物、其製備方法、及其應用 |
CA3008628A1 (en) * | 2015-12-18 | 2017-06-22 | Wellesley Pharmaceuticals, Llc | Composition for reducing frequency of urination, method of making and use thereof |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
CN110049757A (zh) * | 2017-01-11 | 2019-07-23 | 辉凌公司 | 快速崩解的药物组合物 |
KR20190021180A (ko) * | 2017-08-22 | 2019-03-05 | 아주대학교산학협력단 | 퇴행성 신경질환 치료용 복합 제형 조성물 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4052997A (en) | 1996-07-19 | 1998-02-10 | Clarke-Garegg, Margaret A. | Levan derivatives, their preparation, composition and applications including medical and food applications |
SE9803871D0 (sv) | 1998-11-11 | 1998-11-11 | Pharmacia & Upjohn Ab | Therapeutic method and formulation |
GB9908014D0 (en) | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
EP1064938A1 (en) * | 1999-06-28 | 2001-01-03 | Sanofi-Synthelabo | Pharmaceutical dosage forms for controlled release producing at least a timed pulse |
US6509040B1 (en) | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
PT1501534E (pt) * | 2002-05-07 | 2006-09-29 | Ferring Bv | Formulacoes farmaceuticas |
GB0210397D0 (en) | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
US8012505B2 (en) | 2003-02-28 | 2011-09-06 | Alk-Abello A/S | Dosage form having a saccharide matrix |
CN100366294C (zh) | 2004-04-30 | 2008-02-06 | 量子高科(北京)研究院有限公司 | 一种口腔速溶制剂及其生产方法 |
EP1629834A1 (en) | 2004-08-27 | 2006-03-01 | KRKA, D.D., Novo Mesto | Sustained release pharmaceutical composition of tolterodine |
WO2007029087A2 (en) | 2005-09-05 | 2007-03-15 | Ranbaxy Laboratories Limited | Controlled release multiple unit formulations |
US20090192228A1 (en) | 2008-01-28 | 2009-07-30 | Actavis Group Ptc Ehf | Controlled-Release Tolterodine Compositions and Methods |
KR20110075011A (ko) * | 2008-11-10 | 2011-07-05 | (주)아모레퍼시픽 | 서방성 미립자 및 이의 제조방법 |
AU2010277207B2 (en) * | 2009-07-31 | 2014-06-26 | Sun Pharmaceutical Industries Limited | Multi-layered, multiple unit pharmaceutical compositions |
JO3112B1 (ar) * | 2010-03-29 | 2017-09-20 | Ferring Bv | تركيبة دوائية سريعة التحلل |
RU2566269C2 (ru) * | 2010-03-29 | 2015-10-20 | Ферринг Б.В. | Быстрорастворимая фармацевтическая композиция |
MX356601B (es) * | 2010-03-30 | 2018-05-29 | Productos Maver S A De C V | Combinación farmacéutica con efecto antimigrañoso, en presentación sólida de liberación diferenciada. |
US20120135050A1 (en) * | 2010-07-08 | 2012-05-31 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
-
2013
- 2013-11-11 TW TW102140886A patent/TW201422254A/zh unknown
- 2013-11-21 AR ARP130104308A patent/AR093585A1/es unknown
- 2013-11-21 MX MX2015006399A patent/MX2015006399A/es unknown
- 2013-11-21 SG SG11201503913TA patent/SG11201503913TA/en unknown
- 2013-11-21 KR KR1020157015219A patent/KR20150085826A/ko not_active Application Discontinuation
- 2013-11-21 JP JP2015543424A patent/JP2016500088A/ja active Pending
- 2013-11-21 CN CN201380060349.8A patent/CN104797240A/zh active Pending
- 2013-11-21 AU AU2013349682A patent/AU2013349682A1/en not_active Abandoned
- 2013-11-21 IN IN3984DEN2015 patent/IN2015DN03984A/en unknown
- 2013-11-21 EP EP13792703.4A patent/EP2922525A1/en not_active Withdrawn
- 2013-11-21 WO PCT/EP2013/074373 patent/WO2014079922A1/en active Application Filing
- 2013-11-21 BR BR112015011430A patent/BR112015011430A2/pt not_active Application Discontinuation
- 2013-11-21 SG SG10201703388TA patent/SG10201703388TA/en unknown
- 2013-11-21 EA EA201590805A patent/EA201590805A1/ru unknown
- 2013-11-21 CA CA2891365A patent/CA2891365A1/en not_active Abandoned
-
2015
- 2015-05-05 IL IL238648A patent/IL238648A0/en unknown
- 2015-05-15 PH PH12015501096A patent/PH12015501096A1/en unknown
- 2015-05-21 ZA ZA2015/03603A patent/ZA201503603B/en unknown
-
2016
- 2016-02-18 HK HK16101745.8A patent/HK1213779A1/zh unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016500088A5 (ru) | ||
AU2017203246B2 (en) | Extended-release formulation for reducing the frequency of urination and method of use thereof | |
EP3154523A1 (en) | Formulation for oral administration containing mesalazine | |
SG184388A1 (en) | Pharmaceutical formulations for the treatment of overactive bladder | |
ES2623176T3 (es) | Composición farmacéutica de memantina | |
US10213389B2 (en) | Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride | |
AU2017252410A1 (en) | Oral pharmaceutical compositions of mesalazine | |
RU2016147008A (ru) | Жидкие композиции метформина с пролонгированным высвобождением | |
US20070243252A1 (en) | Oral Dosage Formulations and Methods of Preparing the Same | |
US20080069870A1 (en) | Controlled Release Compositions Comprising a Cephalosporin for the Treatment of a Bacterial Infection | |
AU2013293488B2 (en) | Pharmaceutical formulation for reducing frequency of urination and method of use thereof | |
WO2008079102A1 (en) | Modified release loxoprofen compositions | |
JP2016516031A5 (ru) | ||
CN107569690A (zh) | 用于缓解尿频的延长释放制剂及其使用方法 | |
US20070112075A1 (en) | Stable pharmaceutical formulations containing escitalopram and bupropion | |
WO2013158638A1 (en) | Stable dosage forms of skeletal muscle relaxants with extended release coating | |
CN108391420A (zh) | 用于减少排尿频率的组合物及其制备方法和应用 | |
US20090297602A1 (en) | Modified Release Loxoprofen Compositions | |
CN103520136A (zh) | 孟鲁斯特钠脉冲胶囊及其制备方法 | |
CN108135870A (zh) | 延缓、延迟和立即释放型制剂及其制造方法和用途 | |
WO2013103357A1 (en) | Extended-release formulation for reducing the frequency of urination and method of use thereof | |
KR20080031050A (ko) | 높은 ph-의존성 용해도를 갖는 활성 성분에 대해 활성성분이 ph-비의존적으로 지연 방출되는 제약 제제 | |
MX2008004862A (es) | Formulaciones farmacéuticas estables que contienen escitalopram y bupropion | |
CA2874677A1 (en) | Multi-layered, multiple unit pharmaceutical compositions | |
AR064082A1 (es) | Composicion de liberacion modificada de al menos una forma de venlafaxina |